B. Rees

Oral vs parenteral corticosteroids: A clinical controversy

1. Axelrod L: GIucocorticoid therapy. Medicine 55:39-65, 1976. 2. MacGregor RR, Sheagren JN, Mortimer BL, Wolff SM: Alternate-day prednisone therapy; Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. N Engl J Med 280:1427-1432, 1969. 3. Dale DC, Fauci AS, Wolff SM: Alternate-day prednisone: Leukocyte kinetics and susceptibility to infections. N Engl J Med 291:1154-1188, 1974. 4. Fauci AS, Dale DC, Balow JE: Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann Intern Med 84:304-315, 1976. 5. Storrs FJ: Use and abuse of systemic corticosteroid therapy. J AM ACAD DERMATOL 1:95-105, 1979. 6. Arnold HL Jr: Systemic steroid therapy with intramusculaxly injected triamcinolone. South Med J 71: 102-107, 1978. 7. Carson TE, Daane TA, Lee PA, Tredway DR, Wailin JD: Effect of intramuscular triarncinolone acetonide on the human ovulatory cycle. Cuffs 19:633-637, 1977. 8, Mikhail GR, Livingood CS, Mellinger RC, Paige TN, Salyer HL: Effect of long-acting parenteral corticostefolds on adrenal function. Arch Dermatol 100:263-268, 1969. 9. Kusama M, Sakauchi N, Kumaoka S: Studies of plasma levels and urinary excretion after intramuscular injection of triamcinolone acetonide. Metabolism 20:590-596, 1971. I0. Mikhail GR, Sweet LC, Mellinger RC: Parenteral longacting corticosteroids: Effect on hypothalamic-pituitaryadrenal function. Ann Allergy 31:337-343, 1973. 11. Droszcz W, Malunowlcz E, Lech B, Krawczynska H, Madalinska M: Assessment of adrenocortical function in asthmatic patients on long-term triamcinolone acetonide treatment. Ann Allergy 42:41-43, 1979. 121 Dluhy RG, Himathongkam T, Greenfield M: Rapid ACTH test with plasma aldosterone level. Ann Intern Med 80:693-696, 1974. 13. Grant SD, Forsham PH, Di Raimondo VD: Suppression of 17-hydroxycorticosteroids in plasma and urine by single and divided doses of triamcinolone. N Engl J Med 273:1115-1118, 1965. 14. Klinefelter HF, Windenwerder WL, Bledsoe T: Single daily dose prednisone therapy. JAMA 241:2721-2723, 1979. 15. Carson TE, Daane TA, Weinstein RL: Long-term intrarnuscular administration of triamcinolone acetonide: Effect on the hypothalamic-pituitary-adrenal axis. Arch Dermatol 111:1585-1587, 1975. 16. Fine RM: The systemic use of corticosteroids in dermatology. Prog Dermatol 13(No. 3):1-8; 13(No. 4):1-4, 1979. Oral vs parenteral corticosteroids: A clinical controversy

The treatment of warts.

Abstract Management of warts probably will be changed by genetic engineering; early preclinical and clinical trials indicate that a product obtained in this way will be useful in conferring protective immunity. 1 The characterization and immunopathology of warts have been discussed elsewhere in this monograph. The important consideration is that warts may disappear through immune mechanisms. Both cell-mediated and humoral immunity may be of significance. Warts must be treated in a gentle, nonscarring way, because there is considerable evidence that, by repeatedly irritating the wart, the cell walls of the wart may release antigen into the circulation, thus inducing antibody formation.

Forty-nine years of meetings of the American Academy of Dermatology: 1938 to 1987

Abstract Some of the material for this contribution has been excerpted from Dr. Arnolds paper, “Academy Achievements over the Years,” published in the Special Fortieth Anniversary Historical Issue (Fall 1978) of the Bulletin of the American Academy of Dermatology with permission.

Psoriasis: recent advances in diagnosis and management.

The tendency to psoriasis is latent, requiring a causative constellation before lesions become evident. Large, coherent scales which reveal dull, reddish papular lesions when removed are characteristic. Some 29 unusual forms of psoriasis have been differentiated; the intertriginous type may be the most difficult to diagnose. Psoriasis is treated topically and systemically and with physical therapy.

PERSPECTIVES IN DERMATOLOGY: AMERICAN ACADEMY OF DERMATOLOGY 1977

The spacious, beautifully equipped Dallas Convention Center was the site of the Academy‘s 1977 annual meeting, under the presidency of John Shaw of Tacoma, Washington and we were delayed not by elevators but by shuttle buses and lengthy concrete corridors. Still, it was a remarkably efficient operation. Quality control, made possible by Charles Heaton (of Philadelphia) and his evaluation committee, made themselves evident in the program. Attendance by members was 3,268; total physician attendance was 4,071. It was the largest Academy meeting yet.

How We Treat Cutaneous Candidiasis

Cutaneous candidiasis (moniliasis) is treated by counteracting inflammation, preventing further multiplication, and altering predisposing factors.